104 related articles for article (PubMed ID: 12893199)
1. MIB1 as a possible predictor of recurrence in low-grade endometrial stromal sarcoma of the uterus.
Popiolek D; Yee H; Levine P; Vamvakas E; Demopoulos RI
Gynecol Oncol; 2003 Aug; 90(2):353-7. PubMed ID: 12893199
[TBL] [Abstract][Full Text] [Related]
2. Endometrial Stromal Sarcoma Arising from Endometrial Polyp: A Case Report.
Sato S; Ojima Y; Kanda M; Kizaki T; Ohara N
Kobe J Med Sci; 2018 Sep; 64(2):E36-E42. PubMed ID: 30381725
[TBL] [Abstract][Full Text] [Related]
3. Low-grade endometrial stromal sarcoma: hormonal aspects.
Chu MC; Mor G; Lim C; Zheng W; Parkash V; Schwartz PE
Gynecol Oncol; 2003 Jul; 90(1):170-6. PubMed ID: 12821359
[TBL] [Abstract][Full Text] [Related]
4. Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma.
Huvila J; Talve L; Carpén O; Edqvist PH; Pontén F; Grénman S; Auranen A
Gynecol Oncol; 2013 Sep; 130(3):463-9. PubMed ID: 23777659
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of ER, PR, Ki67, c-erbB-2, and p53 in endometrial carcinoma.
Suthipintawong C; Wejaranayang C; Vipupinyo C
J Med Assoc Thai; 2008 Dec; 91(12):1779-84. PubMed ID: 19133508
[TBL] [Abstract][Full Text] [Related]
6. ¹⁸F-Fluorodeoxyglucose uptake and clinicopathological features of recurrent or metastatic endometrial stromal sarcoma.
Inoue K; Tsubamoto H; Kawata S; Hao H; Ikeda Y; Oku N; Hirota S
J Obstet Gynaecol Res; 2014 Feb; 40(2):576-82. PubMed ID: 24118160
[TBL] [Abstract][Full Text] [Related]
7. Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study.
van der Putten LJM; Visser NCM; van de Vijver K; Santacana M; Bronsert P; Bulten J; Hirschfeld M; Colas E; Gil-Moreno A; Garcia A; Mancebo G; Alameda F; Trovik J; Kopperud RK; Huvila J; Schrauwen S; Koskas M; Walker F; Weinberger V; Minar L; Jandakova E; Snijders MPLM; van den Berg-van Erp S; Matias-Guiu X; Salvesen HB; Werner HMJ; Amant F; Massuger LFAG; Pijnenborg JMA
Int J Gynecol Cancer; 2018 Mar; 28(3):514-523. PubMed ID: 29324536
[TBL] [Abstract][Full Text] [Related]
8. Assessment of candidate immunohistochemical prognostic markers of meningioma recurrence.
Csonka T; Murnyák B; Szepesi R; Bencze J; Bognár L; Klekner A; Hortobágyi T
Folia Neuropathol; 2016; 54(2):114-26. PubMed ID: 27543769
[TBL] [Abstract][Full Text] [Related]
9. Clinical implications and prognostic value of single and combined biomarkers in endometrial carcinoma.
Li M; Zhao L; Shen D; Li X; Wang J; Wei L
Chin Med J (Engl); 2014; 127(8):1459-63. PubMed ID: 24762589
[TBL] [Abstract][Full Text] [Related]
10. Expression of progesterone receptor A and B isoforms in low-grade endometrial stromal sarcoma.
Balleine RL; Earls PJ; Webster LR; Mote PA; deFazio A; Harnett PR; Clarke CL
Int J Gynecol Pathol; 2004 Apr; 23(2):138-44. PubMed ID: 15084842
[TBL] [Abstract][Full Text] [Related]
11. Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), p53, ki67, and neu protein in endometrial cancer.
Ferrandina G; Ranelletti FO; Gallotta V; Martinelli E; Zannoni GF; Gessi M; Scambia G
Gynecol Oncol; 2005 Sep; 98(3):383-9. PubMed ID: 15979129
[TBL] [Abstract][Full Text] [Related]
12. Can proliferation biomarkers reliably predict recurrence in World Health Organization 2003 defined endometrial stromal sarcoma, low grade?
Feng W; Malpica A; Skaland I; Gudlaugsson E; Robboy SJ; Dalen I; Hua K; Zhou X; Baak JP
PLoS One; 2013; 8(10):e75899. PubMed ID: 24146786
[TBL] [Abstract][Full Text] [Related]
13. A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma.
Oreskovic S; Babic D; Kalafatic D; Barisic D; Beketic-Oreskovic L
Gynecol Oncol; 2004 Apr; 93(1):34-40. PubMed ID: 15047211
[TBL] [Abstract][Full Text] [Related]
14. Expression of androgen receptors in benign and malignant endometrial stromal neoplasms.
Moinfar F; Regitnig P; Tabrizi AD; Denk H; Tavassoli FA
Virchows Arch; 2004 May; 444(5):410-4. PubMed ID: 15007645
[TBL] [Abstract][Full Text] [Related]
15. Treatment and recurrence patterns in endometrial stromal sarcomas and the relation to c-kit expression.
Geller MA; Argenta P; Bradley W; Dusenbery KE; Brooker D; Downs LS; Judson PL; Carson LF; Boente MP
Gynecol Oncol; 2004 Dec; 95(3):632-6. PubMed ID: 15581975
[TBL] [Abstract][Full Text] [Related]
16. [Clinicopathologic features and prognostic factors of endometrial stromal sarcoma: a study of 55 cases].
Shi JL; Cheng NH; Guo LN; Lian LJ
Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):517-22. PubMed ID: 22169638
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical analysis for therapeutic targets and prognostic markers in low-grade endometrial stromal sarcoma.
Park JY; Kim KR; Nam JH
Int J Gynecol Cancer; 2013 Jan; 23(1):81-9. PubMed ID: 23221606
[TBL] [Abstract][Full Text] [Related]
18. Investigation of hormone receptor expression and its prognostic value in endometrial stromal sarcoma.
Park JY; Baek MH; Park Y; Kim YT; Nam JH
Virchows Arch; 2018 Jul; 473(1):61-69. PubMed ID: 29869299
[TBL] [Abstract][Full Text] [Related]
19. Endometrial stromal sarcoma involving the urinary bladder: a study of 6 cases.
Tian W; Latour M; Epstein JI
Am J Surg Pathol; 2014 Jul; 38(7):982-9. PubMed ID: 24705317
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical markers in differential diagnosis of endometrial stromal sarcoma and cellular leiomyoma.
Zhu XQ; Shi YF; Cheng XD; Zhao CL; Wu YZ
Gynecol Oncol; 2004 Jan; 92(1):71-9. PubMed ID: 14751141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
